GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » ROE %

PetVivo Holdings (PetVivo Holdings) ROE % : -743.10% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is PetVivo Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. PetVivo Holdings's annualized net income for the quarter that ended in Dec. 2023 was $-7.00 Mil. PetVivo Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $0.94 Mil. Therefore, PetVivo Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was -743.10%.

The historical rank and industry rank for PetVivo Holdings's ROE % or its related term are showing as below:

PETV' s ROE % Range Over the Past 10 Years
Min: -8026.37   Med: -259.77   Max: -197.05
Current: -1402.53

During the past 13 years, PetVivo Holdings's highest ROE % was -197.05%. The lowest was -8,026.37%. And the median was -259.77%.

PETV's ROE % is ranked worse than
99.51% of 809 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs PETV: -1402.53

PetVivo Holdings ROE % Historical Data

The historical data trend for PetVivo Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetVivo Holdings ROE % Chart

PetVivo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -197.05 -259.77

PetVivo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -552.61 -1,234.72 -2,061.62 -2,111.61 -743.10

Competitive Comparison of PetVivo Holdings's ROE %

For the Medical Devices subindustry, PetVivo Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetVivo Holdings's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where PetVivo Holdings's ROE % falls into.



PetVivo Holdings ROE % Calculation

PetVivo Holdings's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=-8.718/( (5.987+0.725)/ 2 )
=-8.718/3.356
=-259.77 %

PetVivo Holdings's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-7/( (0.989+0.895)/ 2 )
=-7/0.942
=-743.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


PetVivo Holdings  (OTCPK:PETV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-7/0.942
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7 / 2.384)*(2.384 / 3.846)*(3.846 / 0.942)
=Net Margin %*Asset Turnover*Equity Multiplier
=-293.62 %*0.6199*4.0828
=ROA %*Equity Multiplier
=-182.02 %*4.0828
=-743.10 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-7/0.942
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-7 / -7) * (-7 / -8.536) * (-8.536 / 2.384) * (2.384 / 3.846) * (3.846 / 0.942)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.8201 * -358.05 % * 0.6199 * 4.0828
=-743.10 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


PetVivo Holdings ROE % Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


PetVivo Holdings (PetVivo Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5251 Edina Industrial Boulevard, Edina, MN, USA, 55439
PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.
Executives
James Rudolph Martin director POBOX 53988, IRVINE CA 92619
A.l. Sarroff Fund, Llc 10 percent owner 43 MEADOW WOODS ROAD, GREAT NECK NY 11020
John Spencer Breithaupt director 3041 W. PASADENA DR., BOISE ID 83705
Robert J Costantino director 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joseph William Jasper director 201 SOUTH 11TH STREET, UNIT 1030, MINNEAPOLIS MN 55403
John Lai director, 10 percent owner, officer: CEO 12100 SINGLETREE LANE, SUITE 186, EDEN PRAIRIE MN 55344
Robert James Rudelius director 6913 ARBOR LANE, MCCLEAN VA 22101
Leslie Anne Coolidge director 345 OLD SUTTON ROAD, BARRINGTON HILLS IL 60010
Robert J. Folkes officer: Chief Financial Officer 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Scott Mitchell Johnson director 475 LAKESHORE UNIT #32, INCLINE VILLAGE NV 89451
James Joseph Martin director 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Gregory D Cash director
John Michael Carruth officer: Acting Chief Financial Officer 4923 RIVER WOOD DR., SAVAGE MN 55439
Sherry Grisewood director 377 FAIRMOUNT ROAD, CALIFON NJ 07830
David Don Deming director 16200 45TH STREET SOUTH, AFTON MN 55001